Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Spine Advanced
New York, New York, United Statesaofoundation.org ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Spine BioPharma’s lead candidate, SB-01 For Injection, is a first-in-class synthetic peptide therapy targeting TGF-Beta for degenerative disc disease. The therapy aims to reduce pain, restore function, and slow or stop pathological progression of DDD. SB-01 modulates TGF-Beta activity without eliminating it entirely and has advanced into Phase 3 clinical trials.
- Therapeutic areas
- RheumatologyNeurology
- Modalities
- PeptidesSynthetic peptide
- Industry
- Biotech
02
Partnerships
No specific major pharmaceutical or biotech partnerships are listed on public sources but the company mentions working with pharmaceutical companies and clinicians broadly
Beyond the preview
Go deeper on Spine Advanced.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spine Advanced.